BlackRock, Inc. 13D and 13G filings for Coherus BioSciences, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2025-04-17 09:35 am Sale |
2025-03-31 | 13G | Coherus BioSciences, Inc. CHRS |
BlackRock Inc. BLK |
7,617,701 6.600% |
-3,458,214 (-31.22%) |
Filing |
| 2025-02-05 1:23 pm Sale |
2024-12-31 | 13G | Coherus BioSciences, Inc. CHRS |
BlackRock Inc. BLK |
11,075,915 9.600% |
-998,780 (-8.27%) |
Filing |
| 2024-01-24 09:46 am Purchase |
2023-12-31 | 13G | Coherus BioSciences, Inc. CHRS |
BlackRock Inc. BLK |
12,074,695 10.800% |
428,860 (+3.68%) |
Filing |
| 2023-10-06 2:34 pm Sale |
2023-09-30 | 13G | Coherus BioSciences, Inc. CHRS |
BlackRock Inc. BLK |
11,645,835 10.900% |
-2,433,066 (-17.28%) |
Filing |
| 2023-01-26 08:52 am Unchanged |
2022-12-31 | 13G | Coherus BioSciences, Inc. CHRS |
BlackRock Inc. BLK |
14,078,901 18.100% |
0 (Unchanged) |
Filing |
| 2023-01-20 09:43 am Purchase |
2022-12-31 | 13G | Coherus BioSciences, Inc. CHRS |
BlackRock Inc. BLK |
14,078,901 18.100% |
2,160,046 (+18.12%) |
Filing |
| 2022-01-27 5:14 pm Unchanged |
2021-12-31 | 13G | Coherus BioSciences, Inc. CHRS |
BlackRock Inc. BLK |
11,918,855 15.500% |
0 (Unchanged) |
Filing |
| 2022-01-26 09:16 am Purchase |
2021-12-31 | 13G | Coherus BioSciences, Inc. CHRS |
BlackRock Inc. BLK |
11,918,855 15.500% |
1,390,505 (+13.21%) |
Filing |
| 2021-01-26 2:22 pm Purchase |
2020-12-31 | 13G | Coherus BioSciences, Inc. CHRS |
BlackRock Inc. BLK |
10,528,350 14.600% |
369,351 (+3.64%) |
Filing |
| 2020-06-09 4:32 pm Purchase |
2020-05-31 | 13G | Coherus BioSciences, Inc. CHRS |
BlackRock Inc. BLK |
10,158,999 14.300% |
4,486,780 (+79.10%) |
Filing |